טוען...
Clinical Experience with α-Particle–Emitting (211)At: Treatment of Recurrent Brain Tumor Patients with (211)At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6
α-Particle–emitting radionuclides, such as (211)At, with a 7.2-h half-life, may be optimally suited for the molecularly targeted radiotherapy of strategically sensitive tumor sites, such as those in the central nervous system. Because of the much shorter range and more potent cytotoxicity of α-parti...
שמור ב:
| Main Authors: | , , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2007
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2832604/ https://ncbi.nlm.nih.gov/pubmed/18077533 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.107.046938 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|